Novartis Quarterly Profit Misses Estimates Amid Alcon WoesBy
Drugmaker appoints new CEO for Alcon unit as its sales drop
Novartis forecasts 2016 sales, profit to be unchanged
Novartis AG, Europe’s second-largest drugmaker, posted fourth-quarter earnings that missed analysts’ estimates as revenue at its Alcon eye-care unit continued to plummet and the strength of the U.S. dollar eroded the value of global sales.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.